Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma
Donafenib versus sorafenib for advanced hepatocellular cancer.
HCC
DRUG: Donafenib|DRUG: Sorafenib
Overall Survival, Patient visits are scheduled every 8 weeks to monitor efficacy., 3 years
Progress Free Survival, Patient visits are scheduled every 8 weeks to monitor efficacy.Progressive disease is measured from the date of randomization until dead or disease progression according to Response Evaluation Criteria in Solid Tumors(Version 1.1), 2 years|Percentage of adverse events, Patient visits are scheduled every 4 weeks to monitor safety and drug accountability. Patients were monitored for adverse events by use of the National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE) version 4.0, 3 years
This phase 3 study of donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess efficacy and safety in patients wiht advanced hepatocellular carcinoma (HCC).The study is a randomised,controlled,multicentre study.The controlled drug is sorafenib(Nexavar).The primary endpoint is overall survival.